Replies to post #14288 on ANI Pharmaceuticals (ANIP)

[silvr_surfr]

CG Oncology raised $120M in late 2022, so they don't need our money. It also means our share of the company has shrunk considerably. Perhaps we still have material license rights.

[Just the facts maam]

Slivr, hopefully so. I agree ANI's stake in CG oncology has been diuted but it does look like ANIP may get milestone and royalty payments.

BioSante took a 19.9% stake in Cold Genesys and will get milestones and royalties.

BioSante Pharmaceuticals granted Cold Genesys exclusive, worldwide rights to its oncolytic virus technology in exchange for a 19.9% ownership position in the firm and $95,000 in cash. The deal also covers Phase I CG0070, a replication-competent adenovirus that is being investigated for treatment of superficial bladder cancer. BioSante is also eligible to receive future milestone and royalty payments.

Cold Genesys Buys BioSante’s Oncolytic Virus Technology

I think Merck will end up taking it to market. CG0070 is currently paired with Keytruda in a phase 2 trial

Personally, I think some of the cash will be used to in-licence Nuray Chemicals patent for
Dosage forms of tafamidis and its pharmaceutically acceptable salt thereof. Pfizer's VYNDAQEL franchise brought $686 million last quarter . I see Novitium filing a505(b)(2) as a possibility. After all Samy Shanmugam was the lead inventor in the patent which is set to expire in November 2041.